OpenLB
Open Library of Bioscience
Advanced Search
AIDS (London, England)
07 01, 2022;36 (8): 1129-1134.

Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis.

Jérémy Zeggagh, Rebecca Bauer, Constance Delaugerre, Diane Carette, Lisa Fressard, Isabelle Charreau, Christian Chidiac, Gilles Pialoux, Cécile Tremblay, Eric Cua, Olivier Robineau, François Raffi, Catherine Capitant, Bruno Spire, Laurence Meyer, Jean Michel Molina, Ipergay Study Group
Author Information
  1. Jérémy Zeggagh: Infectious Diseases Department, Hospital Saint-Louis, APHP.
  2. Rebecca Bauer: INSERM, SC 10-US 19.
  3. Constance Delaugerre: Laboratory of Virology, Hopital Saint-Louis, U944 INSERM, CNRS UMR 7212, Institut de Recherche Saint-Louis Paris, Paris.
  4. Diane Carette: INSERM, SC 10-US 19.
  5. Lisa Fressard: Aix Marseille University, IRD, UMR-S912, Marseille.
  6. Isabelle Charreau: INSERM, SC 10-US 19.
  7. Christian Chidiac: Infectious Diseases Department, University Claude Bernard Lyon 1 and Hospices Civils de Lyon, Lyon.
  8. Gilles Pialoux: Infectious Diseases Department, Hospital Tenon, APHP, Paris, France.
  9. Cécile Tremblay: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec, Canada.
  10. Eric Cua: Infectious Diseases Department, Hospital de l'Archet, Nice.
  11. Olivier Robineau: Infectious Diseases Department, Hospital Gustave Dron, Tourcoing.
  12. François Raffi: Department of Infectious Diseases, University Hospital of Nantes, INSERM, Nantes.
  13. Catherine Capitant: INSERM, SC 10-US 19.
  14. Bruno Spire: Aix Marseille Univ, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de L'Information Médicale, Marseille.
  15. Laurence Meyer: INSERM, SC 10-US 19.
  16. Jean Michel Molina: Infectious Diseases Department, Hospital Saint-Louis, APHP.
PMID: 35142708 DOI: 10.1097/QAD.0000000000003187

Abstract

OBJECTIVE: High rates of sexually transmitted infections (STIs) have been reported among pre-exposure prophylaxis (PrEP) users. We wished to assess the incidence and risk factors for recurrent STIs.
DESIGN: The ANRS IPERGAY trial was a prospective study investigating PrEP among MSM and transgender women in outpatient clinics in France and Canada. In all, 429 participants were enrolled, offered up to 4 years of PrEP and screened for bacterial STIs (syphilis, chlamydia and gonorrhea) at baseline and every 6 months.
METHODS: STIs incidence was calculated yearly. Cox proportional hazards model regression was used to explore associations between participants characteristics at baseline and recurrent STI during follow-up.
RESULTS: Over a median follow-up of 23 months, bacterial STI incidence was 75, 33, 13, 32 and 30 per 100 person-years for all STIs, rectal STIs, syphilis, gonorrhea and chlamydia, respectively. STI incidence significantly increased from the first year to the fourth year of the study (55 vs. 90 per 100 person-years, P  < 0.001). During the study period, 167 participants (39%) presented with more than one bacterial STIs which accounted for 86% of all STIs. Baseline risk factors associated with recurrent STIs in a multivariate analysis were an STI at baseline [hazards ratio: 1.48 (95% confidence interval (CI): 1.06-2.07), P  = 0.02], more than eight sexual partners in prior 2 months [hazards ratio: 1.72 (95% CI: 1.21-2.43), P  = 0.002] and the use of gamma-hydroxybutyrate [hazards ratio: 1.66 (95% CI: 1.16-2.38), P  = 0.005].
CONCLUSION: STI incidence was high and increased over time. Most STIs were concentrated in a high-risk group that should be targeted for future interventions.

References

  1. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men . N Engl J Med 2010; 363:2587–2599.
  2. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Preexposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial . Lancet 2016; 387:53–60.
  3. Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection . N Engl J Med 2015; 373:2237–2246.
  4. Molina J-M, Charreau I, Spire B, Cotte L, Chas J, Capitant C, et al. Efficacy, safety, and effect on sexual behaviour of on-demand preexposure prophylaxis for HIV in men who have sex with men: an observational cohort study . Lancet HIV 2017; 3018:1–9.
  5. Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel . JAMA 2020; 324:1651–1669.
  6. Traeger MW, Schroeder SE, Wright EJ, Hellard ME, Cornelisse VJ, Doyle JS, et al. Effects of preexposure prophylaxis for the prevention of human immunodeficiency virus infection on sexual risk behavior in men who have sex with men: a systematic review and meta-analysis . Clin Infect Dis 2018; 67:676–686.
  7. McManus H, Grulich AE, Amin J, Selvey C, Vickers T, Bavinton B, et al. Comparison of trends in rates of sexually transmitted infections before vs after initiation of HIV preexposure prophylaxis among men who have sex with men . JAMA Netw Open 2020; 3:e2030806.
  8. Hoornenborg E, Coyer L, Achterbergh RCA, Matser A, Schim van der Loeff MF, Boyd A, et al. Sexual behaviour and incidence of HIV and sexually transmitted infections among men who have sex with men using daily and event-driven preexposure prophylaxis in AMPrEP: 2 year results from a demonstration study . Lancet HIV 2019; 6:e447–e455.
  9. Serpa JA, Huynh GN, Nickell JB, Miao H. Human immunodeficiency virus preexposure prophylaxis and increased incidence of sexually transmitted infections in the United States . Clin Infect Dis 2020; 70:1884–1890.
  10. Tang EC, Vittinghoff E, Philip SS, Doblecki-Lewis S, Bacon O, Chege W, et al. Quarterly screening optimizes detection of sexually transmitted infections when prescribing HIV preexposure prophylaxis . AIDS 2020; 34:1181–1186.
  11. Jenness SM, Weiss KM, Goodreau SM, Gift T, Chesson H, Hoover KW, et al. Incidence of gonorrhea and chlamydia following HIV preexposure prophylaxis among men who have sex with men: a modeling study . Clin Infect Dis 2017; 65:712–718.
  12. Traeger MW, Cornelisse VJ, Asselin J, Price B, Roth NJ, Willcox J, et al. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection . JAMA 2019; 321:1380–1390.
  13. Molina J-M, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, et al. Postexposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial . Lancet Infect Dis 2018; 18:308–317.
  14. Santé Publique France. Bulletin de santé publique VIH-IST. Décembre 2020. https://www.santepubliquefrance.fr/maladies-et-traumatismes/infections-sexuellement-transmissibles/vih-sida/documents/bulletin-national/bulletin-de-sante-publique-vih-ist.-decembre-2020 ccessed 26 May 2021].
  15. CDC. Sexually Transmitted Disease Surveillance, 2019. Centers for Disease Control and Prevention. United State. 2021. https://www.cdc.gov/std/statistics/2019/default.htm [Accessed 26 May 2021].
  16. Chow EPF, Grulich AE, Fairley CK. Epidemiology and prevention of sexually transmitted infections in men who have sex with men at risk of HIV . Lancet HIV 2019; 6:e396–e405.
  17. Noret M, Balavoine S, Pintado C, Siguier M, Brun A, Bauer R, et al. Daily or on demand oral TDF/FTC for HIV preexposure prophylaxis: experience from an hospital-based clinic in France . AIDS 2018; 32:2161–2169.
  18. Voirin N, Allam C, Charre C, Fernandez C, Godinot M, Oria F, et al. Optimizing strategies for chlamydia trachomatis and Neisseria gonorrhoeae screening in men who have sex with men: a modeling study . Clin Infect Dis 2020; 70:1966–1972.
  19. Nguyen V-K, Greenwald ZR, Trottier H, Cadieux M, Goyette A, Beauchemin M, et al. Incidence of sexually transmitted infections before and after preexposure prophylaxis for HIV . AIDS 2018; 32:523–530.
  20. Zysk C, Williams S, Chavarria I, Wilson H, Balogun A, Jacobs E, et al. Genetic variants in host protein disulfide isomerase 2 (PDIA2) are associated with susceptibility to chlamydia trachomatis infection . J Assoc Genet Technol 2020; 46:244–249.
  21. Grillová L, Musilová J, Janečková K, Pospíšilová P, Kuklová I, Woznicová V, et al. The Arg753Gln polymorphism of Toll-like receptor 2 has a lower occurrence in patients with syphilis, suggesting its protective effect in Czech and Slovak individuals . Infect Immun 2020; 89:e00503–e00520.
  22. Geisler WM, Wang C, Tang J, Wilson CM, Crowley-Nowick PA, Kaslow RA. Immunogenetic correlates of Neisseria gonorrhoeae infection in adolescents . Sex Transm Dis 2008; 35:656–661.
  23. MacGregor L, Kohli M, Looker KJ, Hickson F, Weatherburn P, Schmidt AJ, et al. Chemsex and diagnoses of syphilis, gonorrhoea and chlamydia among men who have sex with men in the UK: a multivariable prediction model using causal inference methodology . Sex Transm Infect 2021; 97:282–289.
  24. Spindler HH, Scheer S, Chen SY, Klausner JD, Katz MH, Valleroy LA, et al. Viagra, methamphetamine, and HIV risk: results from a probability sample of MSM, San Francisco . Sex Transm Dis 2007; 34:586–591.
  25. Hampel B, Kusejko K, Kouyos RD, Böni J, Flepp M, Stöckle M, et al. Chemsex drugs on the rise: a longitudinal analysis of the Swiss HIV Cohort Study from 2007 to 2017 . HIV Med 2020; 21:228–239.
  26. Maxwell S, Shahmanesh M, Gafos M. Chemsex behaviours among men who have sex with men: a systematic review of the literature . Int J Drug Policy 2019; 63:74–89.

MeSH Term

Chlamydia Infections
Female
Gonorrhea
HIV Infections
Homosexuality, Male
Humans
Incidence
Male
Pre-Exposure Prophylaxis
Prospective Studies
Risk Factors
Sexual and Gender Minorities
Sexually Transmitted Diseases
Syphilis
Journal Article
Article has an altmetric score of 6

Word Cloud

Created with Highcharts 10.0.0STIs1incidenceSTIrecurrentPamongPrEPriskfactorsstudyparticipantsbacterialbaselinemonths[hazardsratio:95% = 0sexuallytransmittedinfectionspre-exposureprophylaxisMSMsyphilischlamydiagonorrheafollow-upper100person-yearsincreasedyearCI:OBJECTIVE:HighratesreporteduserswishedassessDESIGN:ANRSIPERGAYtrialprospectiveinvestigatingtransgenderwomenoutpatientclinicsFranceCanada429enrolledoffered4yearsscreenedevery6METHODS:calculatedyearlyCoxproportionalhazardsmodelregressionusedexploreassociationscharacteristicsRESULTS:median237533133230rectalrespectivelysignificantlyfirstfourth55vs90< 0001period16739%presentedoneaccounted86%Baselineassociatedmultivariateanalysis48confidenceintervalCI:06-20702]eightsexualpartnersprior27221-243002]usegamma-hydroxybutyrate6616-238005]CONCLUSION:hightimeconcentratedhigh-riskgrouptargetedfutureinterventionsIncidenceHIV

Similar Articles

Cited By